



## Transgene Announces Upcoming Investor Meetings and R&D Day

---

**Strasbourg, France, April 10, 2017, 6:00 pm CET** – Transgene today announced that management will participate in the upcoming investor events set out below.

- **Kempen 10<sup>th</sup> Life Sciences Conference:** April 19, 2017 - Amsterdam, Netherlands
- **Kepler Biotech Days:** June 9, 2017 - Paris, France

Transgene will host a **“R&D Day”, on June 22, 2017 in Paris, France**. The event which will be conducted in English will feature presentations from several leading international scientists and clinicians.

*Next scheduled financial communication*

1<sup>st</sup> quarter 2017 business update  
April 25, 2017 after market close

### **Contacts**

#### **Transgene:**

**Lucie Larguier**  
Director Corporate Communications & IR  
+33 (0)3 88 27 91 04  
[investorrelations@transgene.fr](mailto:investorrelations@transgene.fr)

#### **Media contacts:**

**Citigate Dewe Rogerson**  
David Dible / Marine Perrier  
+ 44 (0)20 7638 9571  
[transgene@citigatedr.co.uk](mailto:transgene@citigatedr.co.uk)

### **About Transgene**

Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010, a therapeutic vaccine for non-small cell lung cancer and Pexa-Vec, an oncolytic virus for liver cancer. The Company has several other programs in clinical and preclinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China. Additional information about Transgene is available at [www.transgene.fr](http://www.transgene.fr).

Follow us on Twitter: [@TransgeneSA](https://twitter.com/TransgeneSA)